Relationship of 1 year hypokalemia incidence to clinical outcomes in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

被引：0

作者：

Alderman, Michael

Calhoun, David

Cushman, William

Davis, Barry

Eckfeldt, John

Einhorn, Paula

Ford, Charles

Franklin, Stanley

Furberg, Curt

Ong, Stephen

Oparil, Suzanne

Papademetriou, Vasilios

Piller, Linda

Probstfield, Jeffrey

机构：

[1] Albert Einstein Coll Med, Bronx, NY 10467 USA

[2] Univ Alabama, Birmingham, AL USA

[3] Memphis VAMC, Memphis, TN USA

[4] Univ Texas, Sch Publ Hlth, Houston, TX USA

[5] Univ Minnesota Hosp & Clin, Minneapolis, MN 55455 USA

[6] NHLBI, DHVD, Bethesda, MD 20892 USA

[7] Univ Calif Irvine, Los Angeles, CA USA

[8] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA

[9] Ong Med Ctr, Oxon Hill, MD USA

[10] VAMC Washington, Washington, DC USA

[11] Univ Washington, Seattle, WA 98195 USA

来源：

CIRCULATION | 2006年 / 114卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：576 / 576

页数：1

共 50 条

[21] Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
Alderman, Michael H.
Piller, Linda B.
Ford, Charles E.
Probstfield, Jeffrey L.
Oparil, Suzanne
Cushman, William C.
Einhorn, Paula T.
Franklin, Stanley S.
Papademetriou, Vasilios
Ong, Stephen T.
Eckfeldt, John H.
Furberg, Curt D.
Calhoun, David A.
Davis, Barry R.
HYPERTENSION, 2012, 59 (05) : 926 - +
[22] The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?
Beevers, DG
Lee, KW
Lip, GYH
JOURNAL OF HUMAN HYPERTENSION, 2003, 17 (06) : 367 - 372
[23] Clinical outcomes in participants with cardiovascular dysmetabolic syndrome in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
Davis, BR
Black, HR
CIRCULATION, 2004, 110 (17) : 796 - 796
[24] The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT?
D G Beevers
K W Lee
G Y H Lip
Journal of Human Hypertension, 2003, 17 : 367 - 372
[25] Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
Shams, Tanzila
Auchus, Alexander P.
Oparil, Suzanne
Wright, Clinton B.
Wright, Jackson
Furlan, Anthony J.
Sila, Cathy A.
Davis, Barry R.
Pressel, Sara
Yamal, Jose-Miguel
Einhorn, Paula T.
Lerner, Alan J.
STROKE, 2017, 48 (11) : 3078 - +
[26] Clinical implications of recent findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and other studies of hypertension
Furberg, CD
Psaty, BM
Pahor, M
Alderman, MH
ANNALS OF INTERNAL MEDICINE, 2001, 135 (12) : 1074 - 1078
[27] Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Grimm, RH
Margolis, KL
Papademetriou, V
Cushman, WC
Ford, CE
Bettencourt, J
Alderman, MH
Basile, JN
Black, HR
DeQuattro, V
Eckfeldt, J
Hawkins, CM
Perry, HM
Proschan, M
HYPERTENSION, 2001, 37 (01) : 19 - 27
[28] Stroke results in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
Oparil, S
Davis, BR
Nwachuku, C
Pressel, S
deLeon, B
STROKE, 2004, 35 (01) : 235 - 235
[29] Impact of the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) on physician prescribing patterns and patient utilization of antihypertensive medications
Liu, X
Yu, W
Yokoyama, K
VALUE IN HEALTH, 2004, 7 (03) : 334 - 334
[30] Heart failure results in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
Davis, B
EUROPEAN HEART JOURNAL, 2004, 25 : 122 - 122

← 1 2 3 4 5 →